NCT04805788终止2 期
A Phase II Single Arm Trial of Stereotactic Body Proton Radiotherapy (SBPT) for Hepatocellular Carcinoma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Mayo Clinic
- 入组人数
- 9
- 试验地点
- 4
- 主要终点
- 3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC)
研究概览
简要总结
This phase II trial studies the effect of stereotactic body proton radiotherapy in treating patients with liver cancer. Proton radiotherapy is a type of treatment that uses high-energy beams to treat tumors.
详细描述
PRIMARY OBJECTIVE:
I. To determine the 3-month rate of patients experiencing an increase in Child-Pugh (CP) score by 2 or more points of 5-fraction stereotactic body proton radiotherapy (SBPT) in the treatment of hepatocellular carcinoma (HCC).
SECONDARY OBJECTIVES:
I. To determine the 3-month complication rate as defined by grade 3 or higher acute adverse event.
II. To assess late toxicity with 2 year follow-up. III. To estimate the 6-month local control, liver disease control, progression free survival and overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years
- •Radiologically presumed or histologically proven, newly diagnosed or recurrent, hepatocellular carcinoma
- •Clinical stage T0-T4N0M0 (American Joint Committee on Cancer [AJCC] 8th edition).
- •One to three discrete Liver Reporting and Data System-5 (LIRADS-5) lesions that can be encompassed within a single radiation treatment plan
- •Patients treated with external beam radiation as a bridge to transplant are allowed
- •Minimum single lesion size >= 1 cm, maximum cumulative diameter =< 15 cm
- •Vascular involvement (including portal vein, inferior vena cava [IVC] and/or hepatic vein) is allowed
- •Target lesion must be amenable to a SBRT regimen utilizing proton beam therapy (i.e. SBPT)
- •Prior local liver treatment including surgery, percutaneous ablation, transarterial bland or chemoembolization (TACE), or Y-90 radioembolization is allowed if completed at least 6 weeks prior to treatment start date
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
- •Life expectance >= 3 months based on medical comorbidities, tumor extent and other clinical factors as determined by treating physician
- •Child Pugh score of A or B7
- •Absolute neutrophil count (ANC) >= 1000 cells/mm^3 (within 45 days of study entry)
- •Platelets (Plt) >= 30,000 cells/mm^3 (the use of transfusion or other intervention to achieve the minimum platelet level is allowed) (within 45 days of study entry)
- •Hemoglobin (Hgb) >= 8.0 g/dL (the use of transfusion or other intervention to achieve the minimum hemoglobin level is allowed) (within 45 days of study entry)
- •Total bilirubin < 2 mg/dL (within 45 days of study entry)
- •Able to and provides Institutional Review Board (IRB) approved study specific written informed consent
- •Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- •Enrollment on a second independent protocol is allowed if the second protocol intervention will not significantly affect results of the current protocol as determined by the study investigators
排除标准
- •Medical contraindication to receipt of radiotherapy
- •Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- •Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent
- •Active systemic lupus or scleroderma
- •Women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception
- •Prior receipt of external beam radiation to the current active disease site or if additional radiotherapy to the current site would be unsafe as determined by the treating radiation oncologist
- •More than 3 LIRADS-5 lesions or disease extent such that organ at risk constraints cannot be met
- •Tumor extension into common or main branch biliary duct or adjacent organs including stomach, small or large bowel
- •Extrahepatic metastases or lymph node involvement
- •History of other malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 1 year prior to study entry
- •Patient is unable to undergo intravenous contrast enhanced liver imaging (either computed tomography [CT] or magnetic resonance imaging [MRI]) based on clinical imaging protocols established at the treating institution
研究组 & 干预措施
Treatment (SBPT)
Experimental
Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
干预措施: Quality-of-Life Assessment (Other)
Treatment (SBPT)
Experimental
Patients undergo 1 SBPT fraction over 20-30 minutes per day for a total of 5 fractions.
干预措施: Proton Stereotactic Body Radiation Therapy (Radiation)
结局指标
主要结局
3-month rate of patients experiencing an increase in Child-Pugh score by 2 or more points of 5-fraction stereotactic body proton radiotherapy in the treatment of hepatocellular carcinoma (HCC)
时间窗: 3 months
The rate will be estimated and a 95% exact binomial confidence interval reported, and then tested utilizing a one-sample test for proportions versus the historical control of 15%.
次要结局
- 6-month local control(6 months)
- 3-month complication rate(3 months)
- Progression free survival(Up to 2 years)
- Overall survival(Up to 2 years)
- Imaging response rates(6 months)
- Incidence of late toxicity(Up to 2 years)
- Liver disease control(Up to 2 years)
- Value of volumetric imaging analysis(6 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung CancerNon-Small-Cell Lung CarcinomaAdrenal CancerLiver CancerNCT01185639Wake Forest University Health Sciences29
已完成
不适用
Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate CancerStage I Prostate AdenocarcinomaStage II Prostate AdenocarcinomaNCT02470897University of Wisconsin, Madison115
进行中（未招募）
2 期
Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone SurgeryNCT03541850Jonsson Comprehensive Cancer Center92
已完成
1 期
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerMale Breast CarcinomaProstate AdenocarcinomaRecurrent Breast CarcinomaRecurrent Non-Small Cell Lung CarcinomaRecurrent Prostate CarcinomaStage IV Breast CancerStage IV Non-Small Cell Lung CancerStage IV Prostate CancerNCT02206334NRG Oncology42
进行中（未招募）
不适用
Stereotactic Body Radiation Therapy for Breast CancerBreast CancerNCT03585621Toronto Sunnybrook Regional Cancer Centre24